Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Therapy of hepatitis C: from empiricism to eradication.

Pawlotsky JM.

Hepatology. 2006 Feb;43(2 Suppl 1):S207-20. Review.

PMID:
16447262
2.
3.
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.

Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.

Liver Transpl. 2008 Jan;14(1):53-8.

6.

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C; ANRS HCO2 RIBAVIC Study Team.

JAMA. 2004 Dec 15;292(23):2839-48.

PMID:
15598915
7.

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.

Mukherjee S, Rogge J, Weaver L, Schafer DF.

Transplant Proc. 2003 Dec;35(8):3042-4.

PMID:
14697974
8.

Antiviral treatment of hepatitis C: present status and future prospects.

Koike K.

J Infect Chemother. 2006 Oct;12(5):227-32. Epub 2006 Nov 6. Review.

PMID:
17109084
9.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J.

N Engl J Med. 2002 Sep 26;347(13):975-82.

10.
11.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
12.

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT; APRICOT Study Group.

N Engl J Med. 2004 Jul 29;351(5):438-50.

13.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
14.

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.

Int J Artif Organs. 2008 Apr;31(4):295-302.

PMID:
18432584
15.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
16.

Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.

Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R, Simionov I, Vadan R, Parvulescu I, Bancila I.

Rom J Gastroenterol. 2005 Jun;14(2):109-15.

18.

Treatment of hepatitis C in dialysis patients.

Esforzado N, Campistol JM.

Contrib Nephrol. 2012;176:54-65. doi: 10.1159/000332383. Epub 2012 Jan 30. Review.

PMID:
22310781
19.

[Therapy of hepatitis C].

Moradpour D, Blum HE.

Praxis (Bern 1994). 2002 May 29;91(22):977-82. Review. German.

PMID:
12094432

Supplemental Content

Support Center